UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QA
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period Commission File Number 0-8049
ended September 30, 1994
CIRCA PHARMACEUTICALS, INC.
Incorporated under the laws 11-1966265
of the State of New York
(I.R.S. Employer Identification Number)
33 RALPH AVENUE, COPIAGUE, NEW YORK 11726
Telephone number (516) 842-8383
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes No
The number of shares of Common Stock, par
value $.01 per share, outstanding were 21,711,912 as of October 28,
1994.<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
CIRCA PHARMACEUTICALS, INC.
DATE: November 2, 1994 /s/Melvin Sharoky, M.D.
Melvin Sharoky, M.D., President
and Chief Executive Officer
DATE: November 2, 1994 /s/Thomas P. Rice
Thomas P. Rice, Executive Vice President,
Chief Operating and Financial Officer
<PAGE>
[DESCRIPTION] Financial Data Schedule for 1994 Third Quarter 10-Q
[ARTICLE]
[LEGEND] This schedule contains summary financial information
extracted from Circa Pharmaceuticals, Inc. consolidated financial
statements for the quarter ended September 30, 1994 and is
qualified in its entirety by reference to such financial
statements.
[FISCAL-YEAR-END] Dec-31-1994
[PERIOD-END] Sep-30-1994
<period type> Qtr-3
[CASH] 11,770,285
[SECURITIES] 25,822,621
[RECEIVABLES] 636,587
[ALLOWANCES]
[INVENTORY] 1,701,490
[CURRENT-ASSETS] 50,428,673
[PP&E] 12,507,487
[DEPRECIATION]
[TOTAL-ASSETS] 106,333,313
[CURRENT-LIABILITIES] 9,838,517
[BONDS]
[COMMON] 220,792
[PREFERRED-MANDATORY]
[PREFERRED]
[OTHER-SE] 76,071,541
<total-liability-and equity> 106,333,313
[SALES] 1,320,178
<total revenues> 1,320,178
[CGS] 643,951
[TOTAL-COSTS] 5,947,132
<other expenses> 18,555
<loss provisions>
<interest expense>
<income pretax> 3,708,904
[INCOME-TAX] 110,000
<income continuing> 3,598,904
[DISCONTINUED]
[EXTRAORDINARY]
[CHANGES]
[NET-INCOME] 3,598,904
<epa-primary> .17
<epa-diluted> .17
